Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management DOI Creative Commons
Thomas M. Barber, Stefan Kabisch, A. Pfeiffer

et al.

Metabolites, Journal Year: 2025, Volume and Issue: 15(2), P. 85 - 85

Published: Feb. 1, 2025

The ‘Body Mass Index’ (BMI) is an anachronistic and outdated ratio that used as internationally accepted diagnostic criterion for obesity, to prioritise, stratify, outcome-assess its management options. On individual level, the BMI has potential mislead, including inaccuracies in cardiovascular risk assessment. Furthermore, places excessive emphasis on a reduction overall body weight (rather than optimised composition) contributes towards misunderstanding of quiddity obesity dispassionate societal perspective response global problem. objective this review provide overview transitions away from novel vista: viewing skeletal muscle (SM). We resurrect SM tissue hidden plain sight key role plays influencing metabolic health efficiency. discuss complex interlinks between adipose (AT) through myokines adipokines, argue rather two separate tissues, AT should be considered single entity: ‘Adipo–Muscle Axis’. vicious circle sarcopenic which aging- obesity-related decline mass worsened status insulin resistance, turn further compounds function. approaches can mitigate against context negative energy balance, optimisation dietary protein intake resistance physical exercises, molecules development target SM, will play important future obesity. Finally, we Adipo–Muscle Ratio (AMR) would more clinically meaningful descriptor definition help shift our focus regarding effective merely inducing loss optimising AMR with proper attention maintenance augmentation

Language: Английский

Sarcopenic obesity: emerging mechanisms and therapeutic potential DOI Creative Commons
Christopher L. Axelrod, Wagner S. Dantas, John P. Kirwan

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 146, P. 155639 - 155639

Published: June 27, 2023

Sarcopenic obesity, or the loss of muscle mass and function associated with excess adiposity, is a largely untreatable medical condition diminished quality life increased risk mortality. To date, it remains somewhat paradoxical mechanistically undefined as to why subset adults obesity develop muscular decline, an anabolic stimulus generally retention lean mass. Here, we review evidence surrounding definition, etiology, treatment sarcopenic emphasis on emerging regulatory nodes therapeutic potential. We available clinical focused diet, lifestyle, behavioral interventions improve in patients obesity. Based upon evidence, relieving consequences energy burden, such oxidative stress, myosteatosis, and/or mitochondrial dysfunction, promising area for development management

Language: Английский

Citations

60
Sarcopenia and Sarcopenic Obesity and Mortality Among Older People DOI Creative Commons
Elizabeth Benz, Alexandre Pinel, Christelle Guillet

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(3), P. e243604 - e243604

Published: March 25, 2024

Importance Sarcopenia and obesity are 2 global concerns associated with adverse health outcomes in older people. Evidence on the population-based prevalence of combination sarcopenia (sarcopenic [SO]) its association mortality still limited. Objective To investigate SO their all-cause mortality. Design, Setting, Participants This large-scale, cohort study assessed participants from Rotterdam Study March 1, 2009, to June 2014. Associations were studied using Kaplan-Meier curves, Cox proportional hazards regression, accelerated failure time models fitted for sex, age, body mass index (BMI). Data analysis was performed January 1 April 2023. Exposures The SO, measured based handgrip strength composition (BC) (dual-energy x-ray absorptiometry) as recommended by current consensus criteria, probable defined having low confirmed altered BC (high fat percentage and/or appendicular skeletal muscle index) addition strength. Main Outcome Measure primary outcome mortality, collected linked data general practitioners central municipal records, until October 2022. Results In total population 5888 (mean [SD] 69.5 [9.1] years; mean BMI, 27.5 [4.3]; 3343 [56.8%] female), 653 (11.1%; 95% CI, 10.3%-11.9%) had 127 (2.2%; 1.8%-2.6%) sarcopenia. Sarcopenic component present 295 (5.0%; 4.4%-5.6%) components 44 (0.8%; 0.6%-1.0%). An increased risk observed (hazard ratio [HR], 1.29; 1.14-1.47) (HR, 1.93; 1.53-2.43). plus 1.94; 1.60-2.33]) or 2.84; 1.97-4.11) a higher than those without SO. Similar results obtained BMI 27 greater. Conclusions Relevance this study, found be prevalent phenotypes people Additional alterations amplified independently BMI. use first step both diagnoses may allow early identification individuals at premature

Language: Английский

Citations

58
Sarcopenic obesity in older adults: a clinical overview DOI
Carla M. Prado, John A. Batsis, Lorenzo M. Donini

et al.

Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: 20(5), P. 261 - 277

Published: Feb. 6, 2024

Language: Английский

Citations

53
Nutritional considerations with antiobesity medications DOI Creative Commons
Jaime P. Almandoz, Thomas A. Wadden, Colleen Tewksbury

et al.

Obesity, Journal Year: 2024, Volume and Issue: 32(9), P. 1613 - 1631

Published: June 10, 2024

The improved efficacy and generally favorable safety profile of recently approved emerging antiobesity medications (AOMs), which result in an average weight reduction ≥15%, represent significant advancement the treatment obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, monitoring patients treated with AOMs. Prior treatment, clinicians can identify preexisting risk factors counsel their on recommended intakes protein, dietary fiber, micronutrients, fluids. During AOMs, ongoing facilitate early recognition management gastrointestinal symptoms or inadequate nutrient fluid intake. Attention should also be paid other that impact response quality life, such as physical activity social emotional health. In context play active role supporting obesity improve health well-being promote optimal medical outcomes.

Language: Английский

Citations

21
Obesity and body mass index: Past and future considerations in osteoarthritis research DOI Creative Commons
Kristine Godziuk, Gillian Hawker

Osteoarthritis and Cartilage, Journal Year: 2024, Volume and Issue: 32(4), P. 452 - 459

Published: Feb. 12, 2024

Obesity is an important topic for the osteoarthritis (OA) scientific community. However, predominant use of body mass index (BMI) to define obesity in OA research associated with uncertainties and limitations. These include inability discern fat muscle mass, account sex-differences distribution, or identify adiposityrelated health impairments. A focus on BMI may influence weight bias clinical practice impact disparities access effective treatments. To ensure that our understanding approaches improve outcomes individuals at risk continues advance next decade, future will need consider alternative measures beyond identification align evolving science. researchers must be aware issues stigma work minimize negative generalizations based BMI.

Language: Английский

Citations

20
Obesity and menopause DOI Creative Commons
Santiago Palacios, Peter Chedraui, Rafael Sánchez-Borrego

et al.

Gynecological Endocrinology, Journal Year: 2024, Volume and Issue: 40(1)

Published: Feb. 11, 2024

Obesity is not a choice or result of lack willpower, but multifactorial, chronic, progressive, and relapsing disease. During menopause, hormonal body composition changes lead to greater visceral adiposity, that aggravates women’s health at cardiometabolic, mechanic mental level. Adiposity has been identified as an important modifier reproductive hormones. female midlife, obesity associated with menstrual cycle alterations (anovulatory cycles ending abnormal bleedings), menopausal symptoms including hot flashes, poor quality sleep, aches joint pain, genitourinary symptoms, reduced life. However, the relationships between weight, process, aging, hormone levels remain poorly understood. Women have increased risk thromboembolic disease when using menopause therapy (MHT), it probably main medical condition prescribe MHT. this depends on route type The use estrogen-only combined transdermal MHT does increase thrombotic event in women obesity.

Language: Английский

Citations

16
Phase angle is associated with sarcopenic obesity in post-stroke patients DOI
Yoshihiro Yoshimura, Hidetaka Wakabayashi,

Fumihiko Nagano

et al.

Clinical Nutrition, Journal Year: 2023, Volume and Issue: 42(10), P. 2051 - 2057

Published: Aug. 31, 2023

Language: Английский

Citations

23
Identification of factors associated with sarcopenic obesity development: Literature review and expert panel voting DOI Creative Commons
Alexandre Pinel,

C. Guillet,

Frédéric Capel

et al.

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(6), P. 1414 - 1424

Published: April 24, 2024

SummarySarcopenic obesity (SO) is defined as the combination of excess fat mass (obesity) and low skeletal muscle function (sarcopenia). The identification classification factors related to SO would favor better prevention diagnosis. present article aimed (i) define a list with based on literature analysis, (ii) identify clinical conditions linked development from search (iii) evaluate their relevance potential research gaps by consulting an expert panel.From 4746 articles screened, 240 were selected for extraction associated SO. Factors classified according frequency in literature. Clinical also recorded. Then, they evaluated panel evaluation development. Experts suggested additional factors.Thirty-nine unique extracted papers eleven experts field. showed insulin resistance, dyslipidemia, lack exercise training, inflammation hypertension most frequent whereas ranked spontaneous physical activity, protein energy intakes, training aging important.Although presented some differences, this first could help patients at risk Further work needed confirm contribution among population overtime or randomized controlled trials demonstrate causality.

Language: Английский

Citations

13
Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome DOI Creative Commons
Saeid Mirzai, Salvatore Carbone, John A. Batsis

et al.

Current Obesity Reports, Journal Year: 2024, Volume and Issue: 13(3), P. 532 - 544

Published: May 16, 2024

Sarcopenic obesity (SO), defined as the coexistence of excess fat mass and reduced skeletal muscle strength, has emerged an important cardiovascular risk factor, particularly in older adults. This review summarizes recent findings on diagnosis, prevalence, health impacts, treatment SO.

Language: Английский

Citations

13
Strength-to-muscle radiodensity: A potential new index for muscle quality DOI
Jarson Pedro da Costa Pereira, Carla M. Prado, Marı́a Cristina González

et al.

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(7), P. 1667 - 1674

Published: May 22, 2024

Language: Английский

Citations

10